Evidence map›Paper›PMID 36952211›Full record

ArticleHormones (Athens, Greece)2023

Cost-effective genotyping for classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) in resource-poor settings: multiplex ligation probe amplification (MLPA) with/without sequential next-generation sequencing (NGS).

Ana Monteiro, Praveen V Pavithran, Manuprasad Puthukulangara, Nisha Bhavani, Sheela Nampoothiri, Dhanya Yesodharan, Reshma Kumaran

Abstract read
PubMed Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ana MonteiroDepartment of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.
Praveen V PavithranDepartment of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India. pravvp@gmail.com.ORCID http://orcid.org/0000-0003-2678-8847
Manuprasad PuthukulangaraPaediatric Clinical Genetics Laboratory, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
Nisha BhavaniDepartment of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.
Sheela NampoothiriDepartment of Paediatric Genetics, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
Dhanya YesodharanDepartment of Paediatric Genetics, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
Reshma KumaranPaediatric Clinical Genetics Laboratory, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
Amrita Institute of Medical Sciences and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenotyping of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is becoming increasingly significant beyond prenatal counseling in the current era of emerging gene therapy/editing technologies. While the knowledge of common variants helps in designing cost-effective genotyping strategies, limited data are currently available from the Indian subcontinent, especially South India, mainly due to financial constraints. The aim of this study is to assess the genotype of individuals with classic CAH from a South Indian cohort in a cost-effective manner.

methodsThe genotypes of 46 unrelated subjects with classic CAH were studied through initial multiplex ligation-dependent probe amplification (MLPA) using the SALSA MLPA Probe-mix P050 CAH (MRC Holland). Next-generation sequencing (NGS) was done in 10 subjects, as their MLPA was either negative or showed heterozygous variants.

resultsThe common variants observed in our study population of 46 subjects were large deletions (35.8%), intron 2 variant [c.293-13A/C > G] (35.8%), 8 bp del [c.332_339del p.(Gly111Valfs*21)] (7.7%), and R356W [c.1069 C > T p.(Arg357Trp)] (6.6%). MLPA alone detected pathogenic variants in 78.2% of the initial study samples (36/46). Sequential NGS resulted in a 100% detection rate in our study population.

conclusionMLPA appears to be an effective first genotyping modality for this South Indian cohort due to the high prevalence of large deletions and common variants. MLPA as a first initial screening genotyping test with sequential NGS when required may be a cost-effective and highly sensitive approach to CYP21A2 genotyping in our part of the world and in resource-poor settings.

Indexed as

Adrenal Hyperplasia, CongenitalCost-Benefit AnalysisGenotypeHigh-Throughput Nucleotide SequencingHumansMutationSteroid 21-HydroxylaseCYP21A2 protein, humanSteroid 21-HydroxylaseDeletionDuplicationSalt wastingSimple virilizingSouth IndiaVariant

Identifiers

PMID36952211
OpenAlexW4360601136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.